ArticleBiomedical optics express2026
Assessment of the angiogenic potential of xenografted tumors by biomedical imaging techniques.
Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Introduction to the feature issue Photoacoustic Imaging and Sensing: Beyond Fundamentals to Translation.Biomedical optics express · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor angiogenesis promotes tumor growth, metastasis and disease progression. Different cancer types vary in their angiogenic potential, which may influence prognosis and response to therapy. In the present work, we established xenograft models of three of the most aggressive types of human cancers: glioblastoma U87MG, gastric cancer MKN-45, and pancreatic cancer MIA PaCa-2, in immunodeficient mice. The study of vascular network by optoacoustic microangiography revealed the highest degree of vascularization in U87MG xenografts, and the lowest in MIA PaCa-2 xenografts. As shown by PAS-CD31 dual staining, U87MG-derived tumors also showed the highest expression of the endothelial marker CD31 as well as the highest vasculogenic mimicry capacity. In line with this, metabolic imaging by fluorescence Lifetime Imaging Microscopy (FLIM) of nicotinamide adenine dinucleotide (NADH) revealed that MIA PaCa-2 xenografts were the most glycolytic, whereas U87MG had higher levels of oxidative phosphorylation, and MKN-45 showed intermediate values. Therefore, when creating animal models with xenografted tumors, it is important to understand the angiogenic potential of cancer cells, especially for studying drug candidates with an antiangiogenic effect. Also, the combination of optoacoustics and immunohistochemical analysis with FLIM imaging allows for a comprehensive assessment of both vascularization and the metabolic state of the tumor, which can help predict the therapeutic response.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.